C. Farley

814 total citations
20 papers, 605 citations indexed

About

C. Farley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, C. Farley has authored 20 papers receiving a total of 605 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in C. Farley's work include Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Treatment and Pharmacology (4 papers). C. Farley is often cited by papers focused on Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Treatment and Pharmacology (4 papers). C. Farley collaborates with scholars based in United States and United Kingdom. C. Farley's co-authors include John D. Hainsworth, F. Anthony Greco, David R. Spigel, Howard A. Burris, Denise A. Yardley, N. W. Peacock, Jeffrey Patton, Eric Raefsky, Dianna Shipley and Dana S. Thompson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Thoracic Oncology.

In The Last Decade

C. Farley

20 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Farley United States	10	397	282	183	95	76	20	605
A.H. Honkoop Netherlands	10	298 0.8×	107 0.4×	135 0.7×	47 0.5×	78 1.0×	20	577
Joan B. Erland United States	13	796 2.0×	293 1.0×	84 0.5×	61 0.6×	263 3.5×	20	891
Manabu Yamamoto Japan	11	237 0.6×	253 0.9×	160 0.9×	51 0.5×	33 0.4×	26	556
Ji Eun Uhm South Korea	15	340 0.9×	263 0.9×	74 0.4×	96 1.0×	130 1.7×	24	621
M. Bonsignori Italy	10	509 1.3×	162 0.6×	81 0.4×	26 0.3×	42 0.6×	24	602
Don W. Shaffer United States	8	407 1.0×	151 0.5×	138 0.8×	42 0.4×	273 3.6×	11	678
Yoshinori Imura Japan	14	195 0.5×	289 1.0×	120 0.7×	21 0.2×	62 0.8×	51	471
Kuniko Sunami Japan	16	320 0.8×	297 1.1×	150 0.8×	46 0.5×	81 1.1×	47	638
Minghuan Li China	17	368 0.9×	494 1.8×	117 0.6×	80 0.8×	43 0.6×	46	912
G. Baciarello France	7	292 0.7×	212 0.8×	41 0.2×	20 0.2×	119 1.6×	18	440

Countries citing papers authored by C. Farley

Since Specialization

Citations

This map shows the geographic impact of C. Farley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Farley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Farley more than expected).

Fields of papers citing papers by C. Farley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Farley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Farley. The network helps show where C. Farley may publish in the future.

Co-authorship network of co-authors of C. Farley

This figure shows the co-authorship network connecting the top 25 collaborators of C. Farley. A scholar is included among the top collaborators of C. Farley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Farley. C. Farley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hainsworth, John D., David R. Spigel, Howard A. Burris, et al.. (2010). Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site. Cancer. 116(10). 2448–2454. 14 indexed citations

Spigel, David R., F. Anthony Greco, Patrick Murphy, et al.. (2009). Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 4(12). 1555–1560. 67 indexed citations

Infante, Jeffrey R., Denise A. Yardley, Howard A. Burris, et al.. (2009). Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. 9(1). 23–28. 15 indexed citations

Spigel, David R., John D. Hainsworth, Denise A. Yardley, et al.. (2009). Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab. Journal of Clinical Oncology. 28(1). 43–48. 223 indexed citations

Hainsworth, John D., David R. Spigel, John H. Barton, et al.. (2008). Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma. Cancer. 113(4). 765–771. 25 indexed citations

Yardley, Denise A., Howard A. Burris, C. Farley, et al.. (2008). A Phase II Feasibility Trial of Dose-Dense Docetaxel Followed by Doxorubicin/Cyclophosphamide as Adjuvant or Neoadjuvant Treatment for Women with Node-Positive or High-Risk Node-Negative Breast Cancer. Clinical Breast Cancer. 8(3). 242–248. 8 indexed citations

Lunin, Scott D., David R. Spigel, John D. Hainsworth, et al.. (2008). Phase II trial of vinflunine (VFL) in sensitive and refractory relapsed small-cell lung cancer (SCLC): Updated results. Journal of Clinical Oncology. 26(15_suppl). 19028–19028. 2 indexed citations

Spigel, David R., John D. Hainsworth, C. Farley, et al.. (2008). Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC). Journal of Clinical Oncology. 26(15_suppl). 7554–7554. 11 indexed citations

Peacock, N. W., J. R. Infante, DA Yardley, et al.. (2008). Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1032–1032. 3 indexed citations

10.

Spigel, David R., John D. Hainsworth, Howard A. Burris, et al.. (2007). D1-05: Irinotecan, carboplatin, and bevacizumab in untreated extensive-stage small-cell lung cancer. Journal of Thoracic Oncology. 2(8). S391–S391. 2 indexed citations

11.

Hainsworth, John D., David R. Spigel, Jeffrey A. Sosman, et al.. (2007). Treatment of Advanced Renal Cell Carcinoma with the Combination Bevacizumab/Erlotinib/Imatinib: A Phase I/II Trial. Clinical Genitourinary Cancer. 5(7). 427–432. 65 indexed citations

12.

Spigel, David R., John D. Hainsworth, Denise A. Yardley, et al.. (2007). Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with extensive-stage small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 18130–18130. 7 indexed citations

13.

Hainsworth, John D., David R. Spigel, C. Farley, et al.. (2007). Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer. Cancer. 110(9). 2027–2034. 55 indexed citations

14.

Hainsworth, John D., David R. Spigel, C. Farley, et al.. (2007). Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 25(13). 1747–1752. 77 indexed citations

15.

Spigel, David R., F. Anthony Greco, Denise A. Yardley, et al.. (2007). Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with limited-stage small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 18133–18133. 12 indexed citations

16.

Meluch, Anthony A., David R. Spigel, F. Anthony Greco, et al.. (2007). Phase I/II trial of preoperative oxaliplatin, docetaxel, capecitabine, and radiation for localized esophageal cancer. Journal of Clinical Oncology. 25(18_suppl). 4595–4595. 1 indexed citations

17.

Greco, F. Anthony, David R. Spigel, Howard A. Burris, et al.. (2007). Weekly docetaxel versus docetaxel/gemcitabine in elderly/poor performance status (PS) patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC): Randomized phase III trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 25(18_suppl). 7534–7534. 4 indexed citations

18.

Peyton, James D., David R. Spigel, John D. Hainsworth, et al.. (2007). Phase II trial of vinflunine in patients with relapsed small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 18091–18091. 7 indexed citations

19.

Greco, F. Anthony, David R. Spigel, John H. Barton, et al.. (2006). Weekly bortezomib in the treatment of patients (pts) with previously treated multiple myeloma: A phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 24(18_suppl). 7547–7547. 6 indexed citations

20.

Raefsky, Eric, F. Anthony Greco, David R. Spigel, et al.. (2006). Brief duration rituximab(R)/chemotherapy (CNOP or CVP) followed by maintenance rituximab in elderly/poor performance status patients (pts) with diffuse large B-cell lymphoma (DLBCL): A phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 24(18_suppl). 7577–7577. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact